Tag Archives: artificial

#432165 Silicon Valley Is Winning the Race to ...

Henry Ford didn’t invent the motor car. The late 1800s saw a flurry of innovation by hundreds of companies battling to deliver on the promise of fast, efficient and reasonably-priced mechanical transportation. Ford later came to dominate the industry thanks to the development of the moving assembly line.

Today, the sector is poised for another breakthrough with the advent of cars that drive themselves. But unlike the original wave of automobile innovation, the race for supremacy in autonomous vehicles is concentrated among a few corporate giants. So who is set to dominate this time?

I’ve analyzed six companies we think are leading the race to build the first truly driverless car. Three of these—General Motors, Ford, and Volkswagen—come from the existing car industry and need to integrate self-driving technology into their existing fleet of mass-produced vehicles. The other three—Tesla, Uber, and Waymo (owned by the same company as Google)—are newcomers from the digital technology world of Silicon Valley and have to build a mass manufacturing capability.

While it’s impossible to know all the developments at any given time, we have tracked investments, strategic partnerships, and official press releases to learn more about what’s happening behind the scenes. The car industry typically rates self-driving technology on a scale from Level 0 (no automation) to Level 5 (full automation). We’ve assessed where each company is now and estimated how far they are from reaching the top level. Here’s how we think each player is performing.

Volkswagen has invested in taxi-hailing app Gett and partnered with chip-maker Nvidia to develop an artificial intelligence co-pilot for its cars. In 2018, the VW Group is set to release the Audi A8, the first production vehicle that reaches Level 3 on the scale, “conditional driving automation.” This means the car’s computer will handle all driving functions, but a human has to be ready to take over if necessary.

Ford already sells cars with a Level 2 autopilot, “partial driving automation.” This means one or more aspects of driving are controlled by a computer based on information about the environment, for example combined cruise control and lane centering. Alongside other investments, the company has put $1 billion into Argo AI, an artificial intelligence company for self-driving vehicles. Following a trial to test pizza delivery using autonomous vehicles, Ford is now testing Level 4 cars on public roads. These feature “high automation,” where the car can drive entirely on its own but not in certain conditions such as when the road surface is poor or the weather is bad.

General Motors
GM also sells vehicles with Level 2 automation but, after buying Silicon Valley startup Cruise Automation in 2016, now plans to launch the first mass-production-ready Level 5 autonomy vehicle that drives completely on its own by 2019. The Cruise AV will have no steering wheel or pedals to allow a human to take over and be part of a large fleet of driverless taxis the company plans to operate in big cities. But crucially the company hasn’t yet secured permission to test the car on public roads.

Waymo (Google)

Waymo Level 5 testing. Image Credit: Waymo

Founded as a special project in 2009, Waymo separated from Google (though they’re both owned by the same parent firm, Alphabet) in 2016. Though it has never made, sold, or operated a car on a commercial basis, Waymo has created test vehicles that have clocked more than 4 million miles without human drivers as of November 2017. Waymo tested its Level 5 car, “Firefly,” between 2015 and 2017 but then decided to focus on hardware that could be installed in other manufacturers’ vehicles, starting with the Chrysler Pacifica.

The taxi-hailing app maker Uber has been testing autonomous cars on the streets of Pittsburgh since 2016, always with an employee behind the wheel ready to take over in case of a malfunction. After buying the self-driving truck company Otto in 2016 for a reported $680 million, Uber is now expanding its AI capabilities and plans to test NVIDIA’s latest chips in Otto’s vehicles. It has also partnered with Volvo to create a self-driving fleet of cars and with Toyota to co-create a ride-sharing autonomous vehicle.

The first major car manufacturer to come from Silicon Valley, Tesla was also the first to introduce Level 2 autopilot back in 2015. The following year, it announced that all new Teslas would have the hardware for full autonomy, meaning once the software is finished it can be deployed on existing cars with an instant upgrade. Some experts have challenged this approach, arguing that the company has merely added surround cameras to its production cars that aren’t as capable as the laser-based sensing systems that most other carmakers are using.

But the company has collected data from hundreds of thousands of cars, driving millions of miles across all terrains. So, we shouldn’t dismiss the firm’s founder, Elon Musk, when he claims a Level 4 Tesla will drive from LA to New York without any human interference within the first half of 2018.


Who’s leading the race? Image Credit: IMD

At the moment, the disruptors like Tesla, Waymo, and Uber seem to have the upper hand. While the traditional automakers are focusing on bringing Level 3 and 4 partial automation to market, the new companies are leapfrogging them by moving more directly towards Level 5 full automation. Waymo may have the least experience of dealing with consumers in this sector, but it has already clocked up a huge amount of time testing some of the most advanced technology on public roads.

The incumbent carmakers are also focused on the difficult process of integrating new technology and business models into their existing manufacturing operations by buying up small companies. The challengers, on the other hand, are easily partnering with other big players including manufacturers to get the scale and expertise they need more quickly.

Tesla is building its own manufacturing capability but also collecting vast amounts of critical data that will enable it to more easily upgrade its cars when ready for full automation. In particular, Waymo’s experience, technology capability, and ability to secure solid partnerships puts it at the head of the pack.

This article was originally published on The Conversation. Read the original article.

Image Credit: Waymo Continue reading

Posted in Human Robots

#432152 Why Elon Musk Is Stepping Down from AI ...

The move could have implications for artificial intelligence development at Tesla. Continue reading

Posted in Human Robots

#431851 Bend it like Kengoro and Kenshiro

These Japanese humanoids can replicate flexible human-like movement during physical workouts like push-ups, crunches, stretches and other whole-body exercises, to help researchers better understand how humans move during athletic sports, aid in the development of artificial limbs and whole bodies, … Continue reading

Posted in Human Robots

#432036 The Power to Upgrade Our Own Biology Is ...

Upgrading our biology may sound like science fiction, but attempts to improve humanity actually date back thousands of years. Every day, we enhance ourselves through seemingly mundane activities such as exercising, meditating, or consuming performance-enhancing drugs, such as caffeine or adderall. However, the tools with which we upgrade our biology are improving at an accelerating rate and becoming increasingly invasive.

In recent decades, we have developed a wide array of powerful methods, such as genetic engineering and brain-machine interfaces, that are redefining our humanity. In the short run, such enhancement technologies have medical applications and may be used to treat many diseases and disabilities. Additionally, in the coming decades, they could allow us to boost our physical abilities or even digitize human consciousness.

What’s New?
Many futurists argue that our devices, such as our smartphones, are already an extension of our cortex and in many ways an abstract form of enhancement. According to philosophers Andy Clark and David Chalmers’ theory of extended mind, we use technology to expand the boundaries of the human mind beyond our skulls.

One can argue that having access to a smartphone enhances one’s cognitive capacities and abilities and is an indirect form of enhancement of its own. It can be considered an abstract form of brain-machine interface. Beyond that, wearable devices and computers are already accessible in the market, and people like athletes use them to boost their progress.

However, these interfaces are becoming less abstract.

Not long ago, Elon Musk announced a new company, Neuralink, with the goal of merging the human mind with AI. The past few years have seen remarkable developments in both the hardware and software of brain-machine interfaces. Experts are designing more intricate electrodes while programming better algorithms to interpret neural signals. Scientists have already succeeded in enabling paralyzed patients to type with their minds, and are even allowing brains to communicate with one another purely through brainwaves.

Ethical Challenges of Enhancement
There are many social and ethical implications of such advancements.

One of the most fundamental issues with cognitive and physical enhancement techniques is that they contradict the very definition of merit and success that society has relied on for millennia. Many forms of performance-enhancing drugs have been considered “cheating” for the longest time.

But perhaps we ought to revisit some of our fundamental assumptions as a society.

For example, we like to credit hard work and talent in a fair manner, where “fair” generally implies that an individual has acted in a way that has served him to merit his rewards. If you are talented and successful, it is considered to be because you chose to work hard and take advantage of the opportunities available to you. But by these standards, how much of our accomplishments can we truly be credited for?

For instance, the genetic lottery can have an enormous impact on an individual’s predisposition and personality, which can in turn affect factors such as motivation, reasoning skills, and other mental abilities. Many people are born with a natural ability or a physique that gives them an advantage in a particular area or predisposes them to learn faster. But is it justified to reward someone for excellence if their genes had a pivotal role in their path to success?

Beyond that, there are already many ways in which we take “shortcuts” to better mental performance. Seemingly mundane activities like drinking coffee, meditating, exercising, or sleeping well can boost one’s performance in any given area and are tolerated by society. Even the use of language can have positive physical and psychological effects on the human brain, which can be liberating to the individual and immensely beneficial to society at large. And let’s not forget the fact that some of us are born into more access to developing literacy than others.

Given all these reasons, one could argue that cognitive abilities and talents are currently derived more from uncontrollable factors and luck than we like to admit. If anything, technologies like brain-machine interfaces can enhance individual autonomy and allow one a choice of how capable they become.

As Karim Jebari points out (pdf), if a certain characteristic or trait is required to perform a particular role and an individual lacks this trait, would it be wrong to implement the trait through brain-machine interfaces or genetic engineering? How is this different from any conventional form of learning or acquiring a skill? If anything, this would be removing limitations on individuals that result from factors outside their control, such as biological predisposition (or even traits induced from traumatic experiences) to act or perform in a certain way.

Another major ethical concern is equality. As with any other emerging technology, there are valid concerns that cognitive enhancement tech will benefit only the wealthy, thus exacerbating current inequalities. This is where public policy and regulations can play a pivotal role in the impact of technology on society.

Enhancement technologies can either contribute to inequality or allow us to solve it. Educating and empowering the under-privileged can happen at a much more rapid rate, helping the overall rate of human progress accelerate. The “normal range” for human capacity and intelligence, however it is defined, could shift dramatically towards more positive trends.

Many have also raised concerns over the negative applications of government-led biological enhancement, including eugenics-like movements and super-soldiers. Naturally, there are also issues of safety, security, and well-being, especially within the early stages of experimentation with enhancement techniques.

Brain-machine interfaces, for instance, could have implications on autonomy. The interface involves using information extracted from the brain to stimulate or modify systems in order to accomplish a goal. This part of the process can be enhanced by implementing an artificial intelligence system onto the interface—one that exposes the possibility of a third party potentially manipulating individual’s personalities, emotions, and desires by manipulating the interface.

A Tool For Transcendence
It’s important to discuss these risks, not so that we begin to fear and avoid such technologies, but so that we continue to advance in a way that minimizes harm and allows us to optimize the benefits.

Stephen Hawking notes that “with genetic engineering, we will be able to increase the complexity of our DNA, and improve the human race.” Indeed, the potential advantages of modifying biology are revolutionary. Doctors would gain access to a powerful tool to tackle disease, allowing us to live longer and healthier lives. We might be able to extend our lifespan and tackle aging, perhaps a critical step to becoming a space-faring species. We may begin to modify the brain’s building blocks to become more intelligent and capable of solving grand challenges.

In their book Evolving Ourselves, Juan Enriquez and Steve Gullans describe a world where evolution is no longer driven by natural processes. Instead, it is driven by human choices, through what they call unnatural selection and non-random mutation. Human enhancement is bringing us closer to such a world—it could allow us to take control of our evolution and truly shape the future of our species.

Image Credit: GrAl/ Shutterstock.com Continue reading

Posted in Human Robots

#432027 We Read This 800-Page Report on the ...

The longevity field is bustling but still fragmented, and the “silver tsunami” is coming.

That is the takeaway of The Science of Longevity, the behemoth first volume of a four-part series offering a bird’s-eye view of the longevity industry in 2017. The report, a joint production of the Biogerontology Research Foundation, Deep Knowledge Life Science, Aging Analytics Agency, and Longevity.International, synthesizes the growing array of academic and industry ventures related to aging, healthspan, and everything in between.

This is huge, not only in scale but also in ambition. The report, totally worth a read here, will be followed by four additional volumes in 2018, covering topics ranging from the business side of longevity ventures to financial systems to potential tensions between life extension and religion.

And that’s just the first step. The team hopes to publish updated versions of the report annually, giving scientists, investors, and regulatory agencies an easy way to keep their finger on the longevity pulse.

“In 2018, ‘aging’ remains an unnamed adversary in an undeclared war. For all intents and purposes it is mere abstraction in the eyes of regulatory authorities worldwide,” the authors write.

That needs to change.

People often arrive at the field of aging from disparate areas with wildly diverse opinions and strengths. The report compiles these individual efforts at cracking aging into a systematic resource—a “periodic table” for longevity that clearly lays out emerging trends and promising interventions.

The ultimate goal? A global framework serving as a road map to guide the burgeoning industry. With such a framework in hand, academics and industry alike are finally poised to petition the kind of large-scale investments and regulatory changes needed to tackle aging with a unified front.

Infographic depicting many of the key research hubs and non-profits within the field of geroscience.
Image Credit: Longevity.International
The Aging Globe
The global population is rapidly aging. And our medical and social systems aren’t ready to handle this oncoming “silver tsunami.”

Take the medical field. Many age-related diseases such as Alzheimer’s lack effective treatment options. Others, including high blood pressure, stroke, lung or heart problems, require continuous medication and monitoring, placing enormous strain on medical resources.

What’s more, because disease risk rises exponentially with age, medical care for the elderly becomes a game of whack-a-mole: curing any individual disease such as cancer only increases healthy lifespan by two to three years before another one hits.

That’s why in recent years there’s been increasing support for turning the focus to the root of the problem: aging. Rather than tackling individual diseases, geroscience aims to add healthy years to our lifespan—extending “healthspan,” so to speak.

Despite this relative consensus, the field still faces a roadblock. The US FDA does not yet recognize aging as a bona fide disease. Without such a designation, scientists are banned from testing potential interventions for aging in clinical trials (that said, many have used alternate measures such as age-related biomarkers or Alzheimer’s symptoms as a proxy).

Luckily, the FDA’s stance is set to change. The promising anti-aging drug metformin, for example, is already in clinical trials, examining its effect on a variety of age-related symptoms and diseases. This report, and others to follow, may help push progress along.

“It is critical for investors, policymakers, scientists, NGOs, and influential entities to prioritize the amelioration of the geriatric world scenario and recognize aging as a critical matter of global economic security,” the authors say.

Biomedical Gerontology
The causes of aging are complex, stubborn, and not all clear.

But the report lays out two main streams of intervention with already promising results.

The first is to understand the root causes of aging and stop them before damage accumulates. It’s like meddling with cogs and other inner workings of a clock to slow it down, the authors say.

The report lays out several treatments to keep an eye on.

Geroprotective drugs is a big one. Often repurposed from drugs already on the market, these traditional small molecule drugs target a wide variety of metabolic pathways that play a role in aging. Think anti-oxidants, anti-inflammatory, and drugs that mimic caloric restriction, a proven way to extend healthspan in animal models.

More exciting are the emerging technologies. One is nanotechnology. Nanoparticles of carbon, “bucky-balls,” for example, have already been shown to fight viral infections and dangerous ion particles, as well as stimulate the immune system and extend lifespan in mice (though others question the validity of the results).

Blood is another promising, if surprising, fountain of youth: recent studies found that molecules in the blood of the young rejuvenate the heart, brain, and muscles of aged rodents, though many of these findings have yet to be replicated.

Rejuvenation Biotechnology
The second approach is repair and maintenance.

Rather than meddling with inner clockwork, here we force back the hands of a clock to set it back. The main example? Stem cell therapy.

This type of approach would especially benefit the brain, which harbors small, scattered numbers of stem cells that deplete with age. For neurodegenerative diseases like Alzheimer’s, in which neurons progressively die off, stem cell therapy could in theory replace those lost cells and mend those broken circuits.

Once a blue-sky idea, the discovery of induced pluripotent stem cells (iPSCs), where scientists can turn skin and other mature cells back into a stem-like state, hugely propelled the field into near reality. But to date, stem cells haven’t been widely adopted in clinics.

It’s “a toolkit of highly innovative, highly invasive technologies with clinical trials still a great many years off,” the authors say.

But there is a silver lining. The boom in 3D tissue printing offers an alternative approach to stem cells in replacing aging organs. Recent investment from the Methuselah Foundation and other institutions suggests interest remains high despite still being a ways from mainstream use.

A Disruptive Future
“We are finally beginning to see an industry emerge from mankind’s attempts to make sense of the biological chaos,” the authors conclude.

Looking through the trends, they identified several technologies rapidly gaining steam.

One is artificial intelligence, which is already used to bolster drug discovery. Machine learning may also help identify new longevity genes or bring personalized medicine to the clinic based on a patient’s records or biomarkers.

Another is senolytics, a class of drugs that kill off “zombie cells.” Over 10 prospective candidates are already in the pipeline, with some expected to enter the market in less than a decade, the authors say.

Finally, there’s the big gun—gene therapy. The treatment, unlike others mentioned, can directly target the root of any pathology. With a snip (or a swap), genetic tools can turn off damaging genes or switch on ones that promote a youthful profile. It is the most preventative technology at our disposal.

There have already been some success stories in animal models. Using gene therapy, rodents given a boost in telomerase activity, which lengthens the protective caps of DNA strands, live healthier for longer.

“Although it is the prospect farthest from widespread implementation, it may ultimately prove the most influential,” the authors say.

Ultimately, can we stop the silver tsunami before it strikes?

Perhaps not, the authors say. But we do have defenses: the technologies outlined in the report, though still immature, could one day stop the oncoming tidal wave in its tracks.

Now we just have to bring them out of the lab and into the real world. To push the transition along, the team launched Longevity.International, an online meeting ground that unites various stakeholders in the industry.

By providing scientists, entrepreneurs, investors, and policy-makers a platform for learning and discussion, the authors say, we may finally generate enough drive to implement our defenses against aging. The war has begun.

Read the report in full here, and watch out for others coming soon here. The second part of the report profiles 650 (!!!) longevity-focused research hubs, non-profits, scientists, conferences, and literature. It’s an enormously helpful resource—totally worth keeping it in your back pocket for future reference.

Image Credit: Worraket / Shutterstock.com Continue reading

Posted in Human Robots